No. 55Articles
On this page

All reading for this session

· No. 055

Market events

Cue Biopharma (CUE) lost nearly 80% in a session with no new disclosure

Cue Biopharma fell from $14.10 to $2.83 on Nov. 17, with four volatility halts in the first half hour and most volume after 1 p.m. What it reported the night before, and what is unexplained.

Dark headphones hang from the edge of a monitor showing softly blurred purple and amber light.
Dark headphones hang from the edge of a monitor showing softly blurred purple and amber light.

Cue Biopharma (CUE), a clinical-stage biotech, closed at $2.83 on Tuesday, Nov. 17, 2026, down 79.9% from the prior close of $14.10. Volume was 4.23 million shares including extended hours (about 3.8 million in the regular session), compared with about 0.12 million to 0.28 million on each of the previous four sessions. On Nov. 18 the shares rebounded, closing at $4.76 (+68.2%) on 12.5 million shares, per FennEdge's gapper data for that session. FennEdge CUE page

How the session unfolded

FennEdge's minute data shows the decline was spread across the day rather than a single gap:

Time (ET) Price
9:30 a.m. open $13.02
10:06 a.m. first trade below $8
11:44 a.m. below $7
1:38 p.m. below $5
3:17 p.m. below $3
4:00 p.m. close $2.83

Nasdaq halted the stock four times for volatility (LULD pauses) between 9:43 and 9:59 a.m., and trading resumed for the last time at 10:04 a.m. Nasdaq trading halts for Nov. 17 Most of the volume came late. About 2.9 million of the 3.8 million regular-session shares traded after 1 p.m., when the price was already below $7. In after-hours trading the stock printed as low as $2.66.

What Cue reported the evening before

After the close on Nov. 16, Cue filed its third-quarter results. It reported a net loss of $50.0 million ($4.74 per share), revenue of $0.1 million and $57.9 million of cash and cash equivalents at Sept. 30. Nine-month results include a $90.0 million loss on the issuance of liability-classified warrants and related costs. The release restated CUE-221 data and said CUE-401 had begun first-in-human dosing. It gave no cash runway estimate. Nov. 16 Form 8-K and Exhibit 99.1

The quarterly report filed the same evening shows 8,359,523 shares outstanding on Nov. 13, up from 7,753,995 at Sept. 30. It also records a liability for a "top-up share obligation." On Nov. 17, volume equal to about half the shares outstanding changed hands. The filings do not tie either item to the decline.

Cue completed a 1-for-30 reverse split effective April 23, 2026, so prices before that date are not directly comparable without adjustment. April 22 Form 8-K

What is still unknown

  • Why CUE fell 80%. We found no filing, press release or exchange notice beyond the volatility halts.
  • What drove the rebound on Nov. 18.
  • How the warrants and the top-up share obligation work, and whether either leads to additional shares.

Market data in this article is as of 8 p.m. ET on Nov. 18, 2026; filings as of the afternoon of Nov. 18.

This article explains common concepts; examples are not trading recommendations.

This article explains common concepts; examples are not trading recommendations.